Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 187-192

  Fennelly, D ^a   Aghajanian, C ^a   Shapiro, F ^a   O'Flaherty, C ^a   McKenzie, M ^a   O'Connor, C ^a   Tong, W ^a   Norton, L ^a   Spriggs, D ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PACLITAXEL;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; NEUTROPENIA; OVARY CANCER; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT CANCER; TREATMENT PLANNING;

EID: 0031036177     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.187     Document Type: Article

References (28)

1. Silverberg E, Boring C: Cancer Statistics, 1990. CA Cancer J Clin 40:9-26, 1990
2. McGuire WP, Rowinsky EK, Rosenshein NB, et al: Taxol: A unique antineoplastic agent with significant activity in advanced epithelial ovarian neoplasms. Ann Intern Med 111:273-279, 1989
3. Sarosy G, Kohn E, Link C, et al: Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992 (abstr)
4. Swenerton K, Eisenhauer E, ten Bokkel Huinink W, et al: Proc Am Soc Clin Oncol 12:256, 1993 (abstr)
5. Longnecker SM, Donehower RC, Cates AE, et al: High performance liquid chromatographic assay for Taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep 71:53-59, 1987
6. Gershenson D, Kavanagh JJ, Copeland LJ, et al: Re-treatment of patients with recurrent epithelial ovarian cancer with cisplatm-based chemotherapy. Obstet Gynecol 73:798-802, 1989
7. Gore ME, Fryatt I, Wiltshaw E, et al: Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial therapy with these compounds. Gynecol Oncol 36:207-211, 1990
8. Markman M, Rothman R, Hakes T, et al: Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin. J Clin Oncol 9:389-393, 1991
9. Rustin GJS, van der Burg ME, Berek JS: Advanced ovarian cancer. Tumor markers. Ann Oncol 4:S71-77, 1993
10. Georgiadis MS, Russell E, Johnson BE, et al: Prolonging the exposure of human lung cancer cells to paclitaxel improves the cytotoxicity. Proc Am Assoc Cancer Res 35:341, 1994 (abstr)
11. Liebmann JE, Cook JA, Lipshultz C, et al: Cytotoxic studies of paclitaxel (Taxol) in human tumor cell lines. Br J Cancer 68:1104-1109, 1993
12. Zhan Z, Kang Y-K, Regis J, et al: Taxol resistance: In vitro and in vivo studies in breast cancer and lymphoma. Proc Am Assoc Cancer Res 34:215, 1993 (abstr)
13. Kelland LR, Abel G: Comparative in vitro cytotoxicity of Taxol and Taxotere against cisplatin-sensitive and -resistant human ovarian carcinoma cell lines. Cancer Chemother Pharmacol 30:444-450, 1992
14. Lopes NM, Adams EG, Pitts TW, et al: Cell kinetics and cell cycle effects of Taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 32:235-242, 1993
15. Hainsworth JD, Hopkins M, Thomas F, et al: Taxol administered by 1-hour infusion: Preliminary results of a phase I-II study comparing two dose schedules. Proc Am Soc Clin Oncol 13,155:413, 1994 (abstr)
16. Kearns C, Gianni G, Capri G, et al: A comprehensive pharmacokinetic model of paclitaxel and 6-OH-paclitaxel with application to pharmacodynamic relationships in humans. Proc Am Soc Clin Oncol 13,134:332, 1994 (abstr)
17. Gelmon KA, O'Reilly S, Plenderleith IL, et al: Bi-weekly paclitaxel and cisplatin in the treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 13,71:87, 1994 (abstr)
18. Fennelly D, Rigas J, Chou D, et al: Phase I trial of edatrexate plus paclitaxel using an administration schedule with demonstrated in-vitro synergy. Proc Am Soc Clin Oncol 13:365, 1232, 1994 (abstr)
19. Wiernik PH, Schwartz EL, Strauman JJ, et al: Phase I clinical and pharmacokinetic study of Taxol. Cancer Res 47:2486-2493, 1987
20. Brown T, Havlin K, Weiss G, et al: A phase I trial of Taxol as a 6-hour intravenous infusion. J Clin Oncol 9:1261-1267, 1991
21. Feldman E, Seiter K, Helson L, et al: Phase I evaluation of a short infusion every 4 day schedule of Taxol in refractory acute leukemia. Proc Am Soc Clin Oncol 13,311:1022, 1994 (abstr)
22. Donfrancesco D, Deb G, Sio L, et al: Phase I trial of a q4d taxol regimen in pediatric patients with recurrent solid tumors. Proc Am Soc Clin Oncol 13,426:1463, 1994 (abstr)
23. Sarosy G, Kohn E, Link C, et al: Taxol dose intensification in patients with recurrent ovarian cancer. Proc Am Soc Clin Oncol 11:226, 1992 (abstr)
24. Omura GA, Brady MP, Delmore JE, et al: A randomised trial of paclitaxel at 2 dose-levels and filgrastim (GCSF) at 2 doses in platinum pretreated epithelial ovarian cancer. A Gynecological Oncology Group. SWOG, NCCTG and ECOG Study. Proc Am Soc Clin Oncol 15:280, 1996 (abstr)
25. Glantz MJ, Choy H, Kearns CK, et al: Phase I study of weekly outpatient paclitaxel and concurrent cranial irradiation in adults with astrocytomas. J Clin Oncol 14:600-609, 1996
26. Choy H, Akerley W, Safran H, et al: Phase I trial of outpatient weekly paclitaxel and concurrent radiation therapy for advanced non-small-cell lung cancer. J Clin Oncol 12:2682-2686, 1994
27. Klassen U, Wilke H, Strumberg D, et al: Phase I study with a weekly 1-h infusion of paclitaxel in heavily pretreated patients with metastatic breast and ovarian cancer. Eur J Cancer 32A: 547-549, 1996
28. Loeffler TN, Freund W, Lipke J, et al: Schedule and dose-intensified paclitaxel as weekly one-hour infusion: Evidence for an improved toxicity profile and response activity in pretreated solid tumors. Proc Am Soc Clin Oncol 14:470, 1995 (abstr)